Neurodegenerative disease
Conditions
Interventions
JTC-064 or placebo will be administered orally once daily for 28 days.
Sponsors
Yamane Satoshi
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Healthy Japanese male aged from 18 to 45 years (inclusive) at informed consent 2. A subject with a body mass index of 18.5 to less than 25.0 at the screening visit
Exclusion criteria
Exclusion criteria: 1. A subject who has serious medical history of or complications under treatment for the cerebral, liver, kidneys, heart, lungs, gastrointestinal system, hematological, endocrine system, metabolic system, or psychiatric disorders. 2. A subjcet who has a history of gastrointestinal surgery that could interfere with the absorption of the study drug. 3. A subject who has participated in this study and received the study drug administration. 4. A subject who, in the opinion of the Investigator, has impediments to participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety, Pharmacokinetics | — |
Contacts
Public Contactinformation clinical trials
Shionogi & Co.,Ltd.
Outcome results
None listed